Related Experiment Video
Updated: Mar 7, 2026
Mouse Round Spermatid Injection
Published on: January 26, 2024
Current Management of Refractory Germ Cell Tumors and Future Directions
J Clayton Allen1, Austin Kirschner2, Kristen R Scarpato3
1Department of Medicine, Division of Hematology/Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, 691 Preston Research Building, Nashville, TN, 37232, USA.
Purpose Of Review:
We review current management strategies for patients with relapsed and refractory germ cell tumors (GCTs), defined as relapsed or persistent disease following at least one line of cisplatin-based chemotherapy. Additionally, we discuss future directions in the management of these patients.
Recent Findings:
Recent studies involving targeted therapies have been disappointing. Nevertheless, studies of the management of refractory germ cell cancer are ongoing, with a focus on optimal utilization of high-dose chemotherapy and autologous stem cell transplant, as well as the role of immune checkpoint inhibitors in refractory germ cell tumors. Studies aiming to identify those patients who may benefit from more intensive treatment up front to prevent the development of refractory disease are also in progress. Testicular germ cell tumors are among the most curable of all solid tumor malignancies, with cure being possible even in the refractory, metastatic setting. Treatment of refractory disease remains a challenging clinical scenario, but potentially practice changing studies are ongoing.
Insights
Management of relapsed and refractory germ cell tumors (GCTs) is challenging but evolving. Ongoing studies explore intensive chemotherapy, stem cell transplant, and immunotherapy for these difficult-to-treat cancers.
Area of Science:
- Oncology
- Medical Oncology
Background:
- Germ cell tumors (GCTs) are highly curable malignancies.
- Relapsed or refractory GCTs present a significant clinical challenge.
- Cisplatin-based chemotherapy is the standard first-line treatment.
Purpose of the Study:
- To review current management strategies for relapsed and refractory GCTs.
- To discuss future directions in GCT treatment.
- To highlight ongoing research in refractory GCTs.
Main Methods:
- Review of current literature on GCT management.
- Analysis of recent studies on targeted therapies and immunotherapy.
- Discussion of high-dose chemotherapy and autologous stem cell transplant.
Main Results:
- Targeted therapies have shown disappointing results in recent studies.
- High-dose chemotherapy with autologous stem cell transplant remains a key strategy.
- Immune checkpoint inhibitors are being investigated for refractory GCTs.
- Research is ongoing to identify patients who may benefit from upfront intensive treatment.
Conclusions:
- Cure is possible even in refractory, metastatic GCT settings.
- Treatment of refractory GCTs remains challenging but evolving.
- Practice-changing studies are currently in progress.
